Company Amphastar Pharmaceuticals, Inc.

Equities

AMPH

US03209R1032

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-04-29 pm EDT 5-day change 1st Jan Change
42.02 USD +2.21% Intraday chart for Amphastar Pharmaceuticals, Inc. +4.61% -32.06%

Business Summary

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. Its segments include finished pharmaceutical products and API products. The finished pharmaceutical products segment manufactures, markets and distributes Primatene MIST, epinephrine, glucagon, phytonadione, lidocaine, enoxaparin, naloxone, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes RHI API and porcine insulin API for external customers and internal product development. Its pipeline has over 20 product candidates, including generic ANDAs, biosimilar, and others.

Number of employees: 1,761

Sales per Business

USD in Million2022Weight2023Weight Delta
Finished Pharmaceutical Products
97.8 %
487 97.5 % 630 97.8 % +29.55%
Active Pharmaceutical Ingredients
2.2 %
12 2.5 % 14 2.2 % +13.14%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
98.6 %
487 97.6 % 635 98.6 % +30.47%
France
0.7 %
7 1.5 % 5 0.7 % -37.00%
China
0.7 %
5 0.9 % 5 0.7 % -4.09%

Managers

Managers TitleAgeSince
Founder 74 96-02-28
Chief Executive Officer 77 96-02-28
Director of Finance/CFO 56 14-03-31
Chief Tech/Sci/R&D Officer - 10-11-30
Chief Administrative Officer 50 97-05-31
Director/Board Member 64 01-05-31
Public Communications Contact - 23-01-31
Comptroller/Controller/Auditor - 04-06-30
Corporate Officer/Principal 65 98-09-30

Members of the board

Members of the board TitleAgeSince
Director/Board Member 67 03-01-31
Director of Finance/CFO 56 14-03-31
Director/Board Member 64 01-05-31
Director/Board Member 78 05-09-30
Chief Executive Officer 77 96-02-28
Director/Board Member 80 04-07-31
Founder 74 96-02-28
Director/Board Member 62 07-07-31
Chief Administrative Officer 50 97-05-31
Director/Board Member 61 21-06-06

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 60,187,251 38,103,590 ( 63.31 %) 11,321,313 ( 18.81 %) 63.31 %

Shareholders

NameEquities%Valuation
Applied Physics & Chemistry Laboratory, Inc.
16.54 %
7,956,215 16.54 % 349 M $
BlackRock Advisors LLC
12.03 %
5,784,128 12.03 % 254 M $
3,671,300 7.633 % 161 M $
Federated MDTA LLC
6.805 %
3,272,761 6.805 % 144 M $
Vanguard Fiduciary Trust Co.
5.854 %
2,815,596 5.854 % 124 M $
Federated Global Investment Management Corp.
4.502 %
2,165,071 4.502 % 95 M $
LB Hercules Holdings LLC
3.520 %
1,693,002 3.520 % 74 M $
1,471,137 3.059 % 65 M $
Dimensional Fund Advisors LP
2.784 %
1,339,142 2.784 % 59 M $
Fuller & Thaler Asset Management, Inc.
2.647 %
1,273,017 2.647 % 56 M $

Company contact information

Amphastar Pharmaceuticals, Inc.

11570 6th Street

91730, Rancho Cucamonga

+909 980 9484

http://www.amphastar.com
address Amphastar Pharmaceuticals, Inc.(AMPH)

Group companies

NameCategory and Sector
Pharmaceuticals: Major

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
42.02 USD
Average target price
62.6 USD
Spread / Average Target
+48.98%
Consensus
  1. Stock Market
  2. Equities
  3. AMPH Stock
  4. Company Amphastar Pharmaceuticals, Inc.